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Abstract
Glutamic acid decarboxylase is responsible for synthesizing GABA, the major inhibitory neurotransmitter, and exists in two
isoforms—GAD65 and GAD67. The enzyme is cleaved under excitotoxic conditions, but the mechanisms involved and the
functional consequences are not fully elucidated. We found that excitotoxic stimulation of cultured hippocampal neurons
with glutamate leads to a time-dependent cleavage of GAD65 and GAD67 in the N-terminal region of the proteins, and
decrease the corresponding mRNAs. The cleavage of GAD67 was sensitive to the proteasome inhibitors MG132, YU102 and
lactacystin, and was also abrogated by the E1 ubiquitin ligase inhibitor UBEI-41. In contrast, MG132 and UBEI-41 were the
only inhibitors tested that showed an effect on GAD65 cleavage. Excitotoxic stimulation with glutamate also increased the
amount of GAD captured in experiments where ubiquitinated proteins and their binding partners were isolated. However,
no evidences were found for direct GADs ubiquitination in cultured hippocampal neurons, and recombinant GAD65 was not
cleaved by purified 20S or 26S proteasome preparations. Since calpains, a group of calcium activated proteases, play a key
role in GAD65/67 cleavage under excitotoxic conditions the results suggest that GADs are cleaved after ubiquitination and
degradation of an unknown binding partner by the proteasome. The characteristic punctate distribution of GAD65 along
neurites of differentiated cultured hippocampal neurons was significantly reduced after excitotoxic injury, and the total GAD
activity measured in extracts from the cerebellum or cerebral cortex at 24h postmortem (when there is a partial cleavage of
GADs) was also decreased. The results show a role of the UPS in the cleavage of GAD65/67 and point out the deregulation
of GADs under excitotoxic conditions, which is likely to affect GABAergic neurotransmission. This is the first time that the
UPS has been implicated in the events triggered during excitotoxicity and the first molecular target of the UPS affected in
this cell death process.
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Introduction
In traumatic brain injury, epilepsy, and following episodes of
hypoxia-ischemia the excessive release of glutamate and the
consequent overactivation of glutamate receptors leads to cell death
by excitotoxicity [1–4]. Brain ischemia also has a strong impact in
GABAergic neurotransmission. The Ca
2+-dependent exocytotic
release of GABA appears to account for the initial phase of
neurotransmitter release at the onset of ischemia, while the reversal
of the plasma membrane transporters is responsible for much of the
subsequent efflux [5,6]. However, the decrease insurfaceexpression
of post-synaptic GABAA receptors, in part due to their internali-
zation, decreases GABAergic synaptic transmission [7]. Following
transient focal ischemia there is also a decrease in the expression of
the vesicular GABA transporter, which may have a delayed impact
on the exocytotic release of the neurotransmitter [8]. The plasma
membrane GABA transporter GAT1 is a calpain substrate [9], and
calpain activation in the postischemic brain [10] may contribute to
the deregulation of the transporter.
Glutamic acid decarboxylase (GAD) is the key enzyme in the
synthesis of c-aminobutyric acid (GABA) [11] and any alterations
in the activity of the enzyme will also have an impact on the
GABAergic synaptic transmission. GAD exists in two isoforms
encoded by different genes, GAD65 and GAD67, with a
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represents 81% of total GAD in rat hippocampus [13], and is
found predominantly in association with synaptic vesicle mem-
branes in nerve terminals [14–16]. This GAD isoform synthesizes
mainly the vesicular pool of GABA [17,18], and is responsible for
the fine tuning of inhibitory transmission [19]. In contrast, GAD67
is evenly distributed throughout the cell [20], being constitutively
active and accounting for the basal production of the cytosolic
pool of GABA [21]. Both isoforms of GAD are cleaved in
cerebrocortical neurons subjected to excitotoxic conditions by a
mechanism that is sensitive to inhibitors of calpain [22–25], a non-
lysosomal, calcium-activated protease that has been implicated in
excitotoxic neuronal damage [26], and recombinant GAD65 and
67 are cleaved in vitro by calpain [22,23]. Cathepsin inhibitors
also inhibited the cleavage of GAD65 and 67 in cerebrocortical
neurons exposed to a toxic concentration of glutamate, and
recombinant GAD was cleaved by cathepsin L in an in vitro assay
[24]. These evidences suggest that multiple proteolytic systems are
involved in the cleavage of GAD under excitotoxic conditions.
The ubiquitin-proteasome system (UPS) is the major extralyso-
somal system for protein degradation in the cells [27,28]. Proteins
targeted to be degraded by this system are first conjugated by
polyubiquitin chains and then degraded by the proteasomes. The
role of the UPS in cell death in the ischemic brain is rather complex
sincetheactivityof the proteasome is downregulatedinthe ischemic
brain [29,30] but inhibition of the proteasome was found to be
neuroprotective in focal brain ischemia [31–33]. Furthermore, the
effect of proteasome deregulation on the turnover of specific
proteins in the ischemic brain remains to be investigated. Hence, in
the present study we investigated the putative role of the UPS in
GAD cleavage under excitotoxic conditions. In particular the
soluble isoform GAD67 is presentmainly inthe cytoplasm[34] and,
therefore, may constitute a target of the UPS. We found that
excitotoxic stimulation of hippocampal neurons with glutamate
downregulates GADs, both at mRNA and protein levels. Our
results indicate that the UPS does regulate GAD67 cleavage under
excitotoxic conditions, possibly through modulation of an unknown
GAD binding partner. Cleavage of GADs diminished the activity of
the enzyme and the characteristic punctate distribution of GAD65
along neurites was also affected under excitotoxic conditions.
Materials and Methods
Hippocampal cultures
Primary cultures of rat hippocampal neurons were prepared
from the hippocampi of E18-E19 Wistar rat embryos, after
treatment with trypsin (0.06%, for 15min at 37uC; GIBCO-
Invitrogen, Paisley, UK) and deoxyribonuclease I (5.36 mg/ml), in
Ca
2+- and Mg
2+-free Hank’s balanced salt solution (HBSS;
5.36 mM KCl, 0.44 mM KH2PO4, 137 mM NaCl, 4.16 mM
NaHCO3, 0.34 mM Na2HPO4.2H2O, 5 mM glucose, 1 mM
sodium pyruvate, 10 mM HEPES and 0.001% phenol red). The
hippocampi were then washed with HBSS containing 10% fetal
bovine serum (GIBCO-Invitrogen), to stop trypsin activity, and
transferred to Neurobasal medium (GIBCO-Invitrogen) supple-
mented with B27 supplement (1:50 dilution; GIBCO-Invitrogen),
25 mM glutamate, 0.5 mM glutamine and 0.12 mg/ml gentamy-
cin. The cells were dissociated in this solution and were then
plated in 6 well plates (870,000 cells/well) coated with poly-D-
lysine (0.1 mg/mL), or on poly-D-lysine coated glass coverslips, at
a density of 150,000 cells/well (12 well plates). The cultures were
maintained in a humidified incubator of 5% CO2/95% air, at
37uC, for 7 or 10 days. Excitotoxic stimulation was performed with
125 mM glutamate in supplemented Neurobasal medium, for
20 min at 37uC, in a humidified incubator. After stimulation with
glutamate the cells were further incubated with the original culture
medium for the indicated periods of time. When appropriate,
50 mM UBEI-41 (ubiquitin-activating enzyme inhibitor; Biogen-
ova Corp., Maryland, USA), 1 mM MG132 (Calbiochem,
Darmstadt, Germany), 10 mM Lactacystin (Sigma, MO, USA) or
10 mM YU102 (Biomol, Exeter, UK) were added to the incubation
medium 30 min (or 1 h for UBEI-41) before stimulation.
Animals used in the preparation of cell cultures and in the GAD
activity experiments (see below) were handled according to
National and Institutional guidelines. Experiments conducted at
the Center for Neuroscience and Cell Biology were performed
according to the European Union Directive 86/609/EEC on the
protection of animals used for experimental and other scientific
purposes. These experiments did not require approval by an
Institutional Animal Care and Use Committee (IACUC). The
work performed at GNF adhered to the Animal Behavior Society
Guidelines for the Use of Animals in Research, and was approved
by the Institutional Animal Care IACUC.
Preparation of extracts
Hippocampal neurons (DIV7) were washed twice with ice-cold
PBS and once more with PBS buffer supplemented with 1 mM
DTT and a cocktail of protease inhibitors (0.1 mM PMSF; CLAP:
1 mg/ml chymostatin, 1 mg/ml leupeptin, 1 mg/ml antipain, 1 mg/
ml pepstatin; Sigma-Aldrich Quı ´mica, Sintra, Portugal). The cells
were then lysed with RIPA (150 mM NaCl, 50 mM Tris-HCl,
5 mM EGTA, 1% Triton, 0.5% DOC and 0.1% SDS at a final
pH 7.5) supplemented with the cocktail of protease inhibitors.
After centrifugation at 16,100 g for 10 min, protein in the
supernatants was quantified using the bicinchoninic acid (BCA)
assay (Thermo Scientific, Rockford, IL), and the samples were
denaturated with 2x concentrated denaturating buffer (125 mM
Tris, pH 6.8, 100 mM glycine, 4% SDS, 200 mM DTT, 40%
glycerol, 3 mM sodium orthovanadate, and 0.01% bromophenol
blue), at 95uC for 5 min.
Total RNA isolation
Total RNA was extracted from 7 DIV cultured hippocampal
neurons using TRIzolH Reagent (Invitrogen), following the manu-
facturer’s specifications. The content of 2 wells from a 6 well plate,
with 870,000 cells/well (DIV7), was collected for each experimental
condition.Aftertheadditionofchloroformandphaseseparation,the
RNA was precipitated by the addition of isopropanol. The
precipitated RNA was washed once with 75% ethanol, centrifuged,
air-dried and resuspended in 60 ml of RNase-free water (GIBCO-
Invitrogen). The whole procedure was performed at 4uC.
RNA Quality and RNA Concentration
RNA quality and integrity was assessed using the Experion
automated gel-electrophoresis system (Bio-Rad, Amadora, Portu-
gal), as previously described [35]. A virtual gel was created for
each sample, allowing the detection of degradation of the
reference markers, RNA 18S and 28S. Samples showing RNA
degradation or contamination by DNA were discarded. RNA
concentration was determined using both the fluorescent dye
RiboGreen (Invitrogen-Molecular Probes, Leiden, The Nether-
lands) and NanoDrop 1000 (Thermo Scientific). The samples were
aliquoted and stored at -80uC to further use.
Reverse Transcription reaction
For first strand cDNA synthesis 1000 ng of total RNA was
mixed with Random Hexamer Primer p(dN)6 followed by 10 min
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may interfere with the annealing step. The samples were chilled on
ice, and the template-primer mix was then supplemented with
Reaction Buffer (50 mM Tris/HCl, 30 mM KCl, 8 mM MgCl2,
pH 8.5), Protector RNase Inhibitor (20U), dNTPs (1 mM each)
and finally AMV Reverse Transcriptase (10U; Roche, Carnaxide,
Portugal), in a 20 ml final volume. The reaction was performed at
25uC for 10 min, followed by 30 min at 55uC, for primer
annealing to the template and cDNA synthesis, respectively. The
Reverse Transcriptase was then denatured during 5 min at 85uC,
and the samples were then cooled to 4uC for 5 min, and finally
stored at 280uC until further use.
Primer Design
Primers for real-time PCR were designed using the ‘‘Beacon
Designer 7’’ software (Premier Biosoft International, CA, USA),
and the following considerations were taken: (1) GC content about
50%; (2) annealing temperature (Ta) between 5565uC; (3)
secondary structures and primer-dimers were avoided; (4) Primer
length between 18–24 bp; (5) Final product length between 100–
200 bp. The primers used for amplification of GAD65 and
GAD67 were, respectively, NM 012563 (accession number to
mRNA sequence) – 59GCT CAT TGC CCG CTA TAA G39 and
59ATC ACG CTG TCT GTT CCG39; NM 017007 – 59ACA
CTT GAA CAG TAG AGA C39 and 59GCA GGT TGG TAG
TAT TAG G39. The primers used for the amplification of
endogenous controls GAPDH and Tubulin alpha 1a were,
respectively, NM 017008 –59AAC CTG CCA AGT ATG
ATG39 and 59 GGA GTT GCT GTT GAA GTC39 ;N M
022298 –59CAT CCT CAC CAC CCA CAC39 and 59GGA
AGC AGT GAT GGA AGA C39. Following the first experiment
all sets of primers were tested for their specificity in an agarose gel
that allows determination of the product size and possible non-
specific products.
Real-Time PCR
For gene expression analysis 2 ml of 1:100 diluted cDNA was
added to 10 ml 2x SYBR Green Master Mix (Bio-Rad) and the
final concentration of each primer was 250 M in 20 ml total
volume. The thermocycling reaction was initiated with activation
of the Taq DNA Polymerase by heating at 95uC during 30 s,
followed by 45 cycles of a 10 s denaturation step at 95uC, a 30 s
annealing step, and a 30 s elongation step at 72uC. The
fluorescence was measured after the extension step, using the
iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad).
After the thermocycling reaction the melting step was performed
with slow heating, starting at 55uC and with a rate of 0.5uC per 10
s, up to 95uC, with continuous measurement of fluorescence,
allowing detection of possible non-specific products. The assay
included a non-template control and a standard curve (in 10-fold
steps) of cDNA for assessing the efficiency of each set of primers.
All reactions were run in duplicate to reduce confounding variance
[36].
Real Time PCR Data Processing
The threshold cycle (Ct) represents the detectable fluorescence
signal above background resulting from the accumulation of
amplified product, and is a proportional measure of the starting
target sequence concentration. Ct was measured in the exponential
phase and, therefore, was not affected by possible limiting
components in the reaction. For every run performed Ct was set
at the same fluorescence value. Data analysis was performed using
the GenEx (MultiD Analyses, Sweden) software for Real-Time
PCR expression profiling, and the results were normalized with a
set of two internal control genes. Statistical analysis was performed
using the Student’s t test.
Immunoblotting
Protein samples were separated by SDS-PAGE, in 12%
polyacrylamide gels (or 7.5% gels when spectrin products were
detected), transferred to polyvinylidene (PVDF) membranes
(Millipore Corp., Billerica, MA), and immunoblotted. Blots were
incubated with primary antibodies (overnight at 4uC), washed and
exposed to alkaline phosphatase-conjugated secondary antibodies
(1:20000 dilution; 1 h at room temperature) or exposed directly to
ECL in the ubiquitin-conjugates detection which films were
scanned and the optical densities of the bands were measured with
appropriate software. Alkaline phosphatase activity was visualized
by ECF on the Storm 860 Gel and Blot Imaging System (GE
Healthcare, Buckinghamshire, UK). The following primary
antibodies were used: anti-GAD65/67 (1:5000, Sigma), anti-
GAD67 (1:250; BD Biosciences, Erembodegem, Belgium), anti-
body against calpain-mediated fragment of spectrin/fodrin
nSBDP NSBDPs [1:300 [37,38]] and anti-b-Actin (1:5000, Sigma).
Recombinant GAD65 cleavage assay
0.75 mg of recombinant GAD65 (Diamyd Diagnostics, Stock-
holm, Sweden) were incubated with 1.5 mg of 20S or 26S
proteasome (Biomol) at 37uC for 2 h, in a total volume of 20 ml
of buffer (30 mM TrisHCl pH 7.6, 100 mM NaCl, 1 mM CaCl2,
2 mM MgCl2, 50 mM ATP, 1 mM DTT, 5% (v/v) glycerol), with
or without 10 mM MG132. A pre-incubation of 5 min with the
proteasome inhibitor was performed. Reactions were stopped by
addition of 20 ml of 2x concentrated denaturating buffer (same for
immunoblot), resolved by 12% PAGE and probed with a GAD65
antibody by Western blot.
Purified proteasome activity
To test for the activity of the purified proteasome activity, the
20S and 26S proteasome preparations were incubated in the
presence of the chymotrypsin-like fluorogenic peptide suc-LLVY-
MCA (Peptide Institute, Inc., Osaka, Japan). The proteasome
preparations were incubated with the substrate (50 mM) in the
presence or in the absence of the proteasome inhibitor MG132
(10 mM), in a medium containing 1 mM EDTA, 10 mM tris-HCl
(pH 7.5), 20% glycerol, 4 mM DTT, 2 mM ATP (100 ml final
volume). Substrate degradation by the proteasome was monitored
every 5 min during 1 h at 37uC in a fluorescence-luminescence
detector (Synergy
TM HT Multi-Mode Microplate Reader, BioTek,
Winooski, VT), set to 380 and 460 nm, excitatory and emission
wavelengths, respectively.
Immunoprecipitation Assay
Immunoprecipitation of ubiquitin-conjugated proteins was
performed using the Ubiqapture – Q Kit (Biomol, Exeter, UK),
as described by the manufacturer. A total of 50 mg lysates from
cultured hippocampal neurons were used per assay. Samples were
added to the tubes containing 80 ml UbiQapture-Q matrix and
incubated overnight at 4uC in an horizontal rotor mixer. The
matrix was then carefully washed and the ubiquitin-protein
conjugates were eluted by addition of 160 ml of PBS and 50 ml
of 5X concentrated denaturating buffer (same for immunoblot).
Samples were quenched by incubation during 15 min at 4uCo n
an horizontal rotor and then denaturated by heating during at
95uC for 10 min. The eluted fraction was clarified from the matrix
pellet by centrifugation at 16,100 g during 10 min. Western blot
analysis was performed as previously described using an anti-
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supplied by the kit, applying equal sample volumes (approximately
60 ml).
Measurement of GAD activity
Wistar adult rats were decapitated and each head was covered
and kept at room temperature (approximately 21uC) for 24 h.
Brains were then dissected and placed on an ice-cold plate for
dissection of the cerebellum and cerebral cortex. Samples were
then resuspended in 50 mM TrisHCl and 0.02% Triton X-100,
sonicated with a probe sonicator in 5 pulses of 5 seconds, and
centrifuged at 16,100 g for 10 min. The supernatants were diluted
(1:30–1:100) and the protein content was measured using the BCA
method. Activity of glutamate decarboxylase (GAD) was measured
by the [
14C]CO2 trapping method, using L-[1-
14C]-glutamic acid
(60 mCi/mmol, GE Healthcare, Buckinghamshire, UK) as a
substrate [39]. Enzyme activity was expressed as nmol of product/
h/mg of protein. Reactions contained 40 mg of extract protein and
0.5 M KH2PO4, 5 mM ethylenediamineteraacetic acid (EDTA),
1 mM 2-aminoethyliso-thiouronium bromide (AET), 10 mM
glutamate, 1 mM pyridoxal phosphate and L-[1-
14C]-glutamic
acid in a total volume of 100 ml. Samples were incubated for 1 h at
37uC in test tubes containing #32 glass fiber filters (Schleider and
Schuell, Keene, NH, USA) coated with 0.5 M Solvable (Packard
Instruments, CT, USA). Each filter was suspended at the top of the
tube, just underneath a rubber stopper, which sealed the tube. The
reaction was stopped by the injection of 15% trichloroacetic acid
through the stopper. The tubes were incubated at room
temperature for another 120 min to ensure complete release and
absorption of [
14C]CO2 into the filter paper. The filter papers
were then removed from the tubes and placed in scintillation vials
for measurement of the [
14C]CO2 product in a Packard 2000
spectrometer provided with dpm correction. The scintillation
cocktail used contained 5.84 g 2,5-diphenyloxazole (PPO) and
133.6 mg of 1,4-Bis(5-phenyl-2-oxazolyl)benzene (POPOP),
800 ml toluene and 200 ml of Triton X-100. Sample extracts
were also analysed by Western Blot using the anti-GAD65/67
antibody.
Immunocytochemistry
For immunocytochemistry, cultured hippocampal neurons were
grown on poly-D-lysine coated glass coverslips, at a density of
45610
3 cells/cm
2, and were then fixed in PBS supplemented with
4% paraformaldehyde/4% sucrose, for 30 min at 4uC. After
fixation the cells were permeabilized with 0.25% Triton X-100 in
PBS, for 5 min at room temperature, washed three times in PBS,
and then blocked with 20% normal goat serum, for 1 h at room
temperature, and stained against VGLUT1 (1:1000; Synaptic
Systems) + VGLUT2 (1:500; Synaptic Systems) or GABA (1:2000;
SIGMA) overnight at 4uC. Next, the cells were washed six times
and incubated for 1 h at room temperature with the secondary
antibody (Alexa FluorH 488 goat anti-rabbit, 1:500 to 1:1000;
Barcelona, Spain). The cells were washed three times, mounted on
glass slides with the Dako mounting medium and viewed on an
Axiovert 200 fluorescence microscope coupled to an Axiocam
HRm digital camera (Zeiss) (Figure 1).
Immunocytochemistry experiments for localization of GAD65
were performed using hippocampal neurons maintained in culture
for 10 days. The cells were fixed with 4% formaldehyde, 4%
sucrose in PBS for 12 min at room temperature and were
subsequently permeabilized with 0.25% Triton X-100 in PBS for
3 min, washed 3 times in PBS and incubated in blocking solution
(2% bovine serum albumin, 2% glycine, and 0.2% gelatin in
50 mM NH4Cl) for 1 h at room temperature. Afterwards, the
neurons were incubated for 1 h with a mouse monoclonal
antibody anti-GABAAReceptor b2/3 (Upstate Biotechnology) at
a dilution of 1:200, and a rabbit polyclonal antibody anti-GAD65
(SIGMA) at a dilution of 1:1000, in blocking solution. Following
the incubation with the primary antibodies, the cells were rinsed 4
times in PBS during 15 min periods, incubated for 1 h at room
temperature with secondary antibodies Alexa Fluor 568 goat anti-
rabbit and Alexa Fluor 488 goat anti-mouse (Invitrogen), at a
dilution of 1:500 in blocking solution, rinsed 3 times in PBS
followed by a final rinse in deionized water, dried, and mounted in
Vectashield mounting solution (Vector Laboratories, Inc.). The
neurons were imaged at the Garner Laboratory (Stanford
University) with a Zeiss Axovert 200M microscope using a 63x
objective. The image emission was directed through a CSU10
spinning disk confocal unit (Yokogawa) and collected by a 512B-
CCD camera (Roper Scientific). Image acquisition and analysis
was conducted with Metamorph software. For each field of view,
stacks of 2 images with a Z step size of 0.2 mm were collected and
a Metamorph 3D reconstruction tool was used to create a
projection image. For each condition, 15 images were collected
from two different cover slips.
For quantitative assessment of GABAAReceptor b2/3 and
GAD65 protein co-localization, the 3D reconstruction stacked
images were submitted to threshold using the MetaMorph
Inclusive Threshold application, in order to include only the
puncta labeled by the GAD65 antibody. The total number of
GAD65 puncta was determined using Integrated Morphometry
Analysis of the image and selecting the Area parameter setup for
measurement. After proceeding to perform an identical 3D
reconstruction and threshold of the GABAAReceptor b2/3
corresponding image, the two reconstructed images were over-
layed and a color threshold was set. Finally, the overlay image was
used to quantify the number of puncta positive for both
GABAAReceptor b2/3 and GAD65, using the Integrated
Morphometry Analysis tool. This procedure was repeated for
each field of view, and the ratio of GABAAReceptor b2/3 subunits
and GAD65 positive puncta per total number to GAD65 puncta
was determined in percentage. The average number of 15 images,
per condition, was calculated for 3 independent experiments.
Likewise, the number of GAD65 puncta per unit length of axon
was determined by selecting the option Trace Region on
MetaMorph to delineate segments of axons with at least
100 mm, and measuring the number of GAD65 puncta on the
image previously submitted to a threshold, using Integrated
Morphometric Analysis. The length of each axonal segment was
determined selecting the Multi-line tool and uniting consecutive
puncta along the delineated neurite. This procedure was repeated
in each field of view, for 10–15 images per condition, in each of
the 3 independent neuronal preparations.
Determination of the viability of GABAergic neurons with
Hoescht 33342
Determination of cell viability was performed by fluorescence
microscopy, using the indicator Hoechst 33342 as previously
described [40]. The cells were stimulated with 125 mM glutamate
for 20 min, in Neurobasal medium supplemented with the GABA
transporter inhibitor SKF89976 (10 mM). After the excitotoxic
insult hippocampal neurons were further incubated in culture
conditioned medium supplemented with 10 mM SKF89976 for
12 h. Incubation of the cells with SKF89976 during stimulation
with glutamate and after the excitotoxic insult prevents the
depletion of GABA through reversal of the plasma membrane
transporter [41]. GABAergic neurons were stained using an anti-
GABA polyclonal antibody (see above), and the nuclear morphol-
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the nuclear morphology was limited to GABAergic neurons,
stained with the anti-GABA antibody.
Measurement of metabolic activity with CellTiter-Glow
Rat hippocampal neurons cultured in 384 micro-titter plates,
coated with poly-D-lysine, at a density of 91.6610
3 cells/cm
2 were
incubated with 125 ı `M glutamate in supplemented Neurobasal
medium, for 20 min at 37uC. After stimulation with glutamate, the
cells were further incubated with the original culture medium, for
14 h at 37uC. The viability of the cells was then measured by
analysing the levels of ATP as an indicator of cellular metabolic
activity, using CellTitter-Glo (Promega) according to manufactur-
er’s instructions. Briefly, in each well, 50 ı `l of PBS/CellTitter-Glo
(1:1) were dispensed with a Multidrop 384 stacker (Titertek), after
removal of the growth media, at room temperature. The plate was
then placed on an orbital shaker for 2 minutes, at maximum speed
and further incubated for 10 minutes at room temperature, without
shaking. Luciferase luminescence was measured immediately
afterwards, using an Acquest plate reader (Molecular Devices).
Figure 1. Glutamate excitotoxicity decreases viability of cultured hippocampal GABAergic neurons. GABAergic and glutamatergic
neurons in the cultures (DIV7) were identified by immunocytochemistry, using antibodies against GABA (A, E) and VGLUT1+2 (A, D). The total
number of cells present in the analysed fields was calculated based on the number of nuclei, stained with the fluorescent dye Hoechst 33342. Data
are presented as mean6SEM of 5 independent preparations (A). Excitotoxic stimulation of hippocampal neurons was performed by incubation
with 125 mM glutamate, for 20 min, in fresh Neurobasal medium containing B27 supplement, and the cells were further incubated in the original
medium for 14 h. Cell death was assessed with the recombinant Luciferase chemoluminescence assay with CellTiterGlo (B), or by fluorescence
microscopy using the fluorescence dye Hoechst 33342 (C). In the latter condition GABAergic cells were identified by immunocytochemistry, using
an antibody against GABA. Data are presented as mean6SEM of 5 independent experiments. Statistical analysis was performed using Student’s t-
test. ***p,0.001.
doi:10.1371/journal.pone.0010139.g001
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Statistical analysis was performed using one-way ANOVA
analysis of variance followed by the Bonferroni test, or using the
Student’s t test, as indicated in the figure captions.
Results
Excitotoxic damage of cultured GABAergic hippocampal
neurons
Dissociated cultures of hippocampal neurons contain gluta-
matergic and GABAergic neurons, expressing the vesicular
glutamate transporter 1 (VGLUT1) and glutamic acid decarbox-
ylase, respectively [42]. Immunocytochemistry experiments using
antibodies against VGLUT1+VGLUT2 (Fig. 1D) and against
GABA (Fig. 1E) showed that 65% of the cells present in
hippocampal cultures are glutamatergic and 5% are GABAergic,
respectively (Fig. 1A).
Excitotoxic stimulation of cultured hippocampal neurons with
125 mM glutamate for 20 min reduced cell viability as determined
using the CellTiter-Glo Luciferase chemiluminescence assay, a
method based on the quantification of the ATP present in the cells.
Luciferase activity was reduced to 48% of the control 14 h after
the toxic insult (Fig. 1B), in agreement with the results obtained in
experiments where cell survival was determined using fluorescence
microscopy with the indicator Hoechst 33342 [40]. Under these
conditions damaged hippocampal neurons display an apoptotic-
like morphology. Since GABAergic neurons represent a minor
fraction of the cells present in the cultures, we have specifically
assessed the effects of excitotoxic stimulation with glutamate on the
neuronal population displaying GABA immunoreactivity. In these
experiments the cells were stimulated with glutamate in the
presence of the GABA transporter inhibitor SKF89976 in order to
prevent the release of the neurotransmitter through reversal of the
plasma membrane transporter [41]. The number of GABAergic
cells displaying apoptotic-like morphology 12 h after glutamate
stimulation was about 54% (Fig. 1C).
Excitotoxicity-induced cleavage of GAD and down-
regulation of gene expression
To test the effect of glutamate stimulation on glutamic acid
decarboxylase, a marker of GABAergic neurons, GAD protein
levels were evaluated after the excitotoxic insult, using an antibody
that recognizes both forms of the enzyme in a common C-terminal
region (Fig. 2C). Under control conditions the antibody allows
identifying the two GAD isoforms, with 67 kDa and 65 kDa.
Glutamate stimulation induced a time-dependent decrease in the
abundance of both isoforms, and this effect was correlated with the
upregulation of a truncated form with an apparent molecular mass
of 55–58 kDa (Fig. 2A). The truncated form still bound the C-
terminus directed antibody, but no smaller immunoreactive forms
of GAD were detected in the blots (not shown). These results
indicate that glutamate-induced cleavage of the two GAD isoforms
occurs at the N-terminal region and gives rise to truncated forms
with similar apparent molecular weights.
In order to further characterize the cleavage of GAD under
excitotoxic conditions, we tested a GAD67 specific antibody that
binds its N-terminus (amino acids 17–130). The immunoreactivity
pattern in extracts prepared from cells incubated for 14 h after the
toxic insult with glutamate was similar to that obtained using the
antibody directed against the C-terminal region of GAD (Fig. 2B).
This indicates that GAD67 is cleaved before amino acid 130.
Besides its effect in inducing the cleavage of GAD, excitotoxic
stimulation with glutamate may also have delayed effects on GAD
by acting at the transcription level. This was tested by Real-Time
PCR, in cells subjected to excitotoxic stimulation with glutamate
for 20 min and further incubated in culture medium for 4 h.
Under these conditions there was a 58% and 71% downregulation
of GAD65 and GAD67 mRNA, respectively, relative to
unstimulated cells (Fig. 3).
Proteasome inhibitors protect GAD65/67 from cleavage
under glutamate-induced excitotoxicity in hippocampal
neurons
Multiple proteolytic systems have been shown to participate in
the cleavage of GAD under excitotoxic conditions, including
calpains and cathepsins [22–25]. Despite the key role of the
ubiquitin-proteasome system (UPS) in protein degradation in the
CNS, no studies have addressed its role in the down-regulation of
full-length GAD isoforms under excitotoxic conditions. To test for
the effect of inhibiting different proteolytic activities of the
proteasome, we used the chymotrypsin-like activity directed
inhibitor MG132 and the post-glutamyl peptide hydrolyzing-
activity (PGPH) directed inhibitor YU102. We also tested the
effect of lactacystin which shows a slight preference for the trypsin-
like and caspase-like activities [43]. MG132 is a synthetic peptide
aldehyde that binds reversibly to the 20S proteasome active site
forming a covalent hemiacetal adduct [44,45]. The effect of
proteasome inhibitors was tested 5 h after the toxic insult with
glutamate since long incubation periods with these compounds
causes neuronal cell death [46,47]. MG132 abrogated glutamate-
induced cleavage on both isoforms of GAD, as determined 5 h
after the toxic insult (Fig. 4A). Lactacystin is a Streptomyces
lactacystinaeus metabolite that targets the 20S proteasome by an
irreversible modification of the amino terminal threonine of b-
subunits, while YU102 is a a9, b9-epoxyketine, the only peptidyl-
glutamylpeptidehydrolyzing (PGPH)-specific peptide used in this
study [45,48]. Both YU102 and lactacystin inhibited glutamate-
evoked GAD65 cleavage, but were without effect on GAD67
(Fig. 4A).
To further characterize the role of the UPS in the glutamate-
evoked cleavage of GAD we tested the effect of the ubiquitin-
activating enzyme (E1) inhibitor, UBEI-41 [49]. It has been
assumed that only a single activating enzyme for ubiquitin exists,
which operates at the initial step of the ubiquitin-proteasome
pathway. Therefore, if the UPS plays a role in the cleavage of
GAD, inhibitors of E1 should abrogate the excitoxicity-induced
cleavage of the GAD. Accordingly, inhibition of the ubiquitin-
activating (E1) enzyme prevented the effect of excitotoxic
stimulation on the cleavage of GAD67 and GAD65 (Fig. 4B).
In previous studies the cleavage of GAD under excitotoxic
conditions was found to be abrogated by calpain inhibitors [22–
25]. Furthermore, recombinant GAD65 and 67 are cleaved in
vitro by calpain [22,23]. Accordingly, incubation of hippocampal
neurons with ALLN, a chemical inhibitor that targets preferen-
tially calpains when used at lower concentrations, prevented the
glutamate-induced cleavage of GAD65/67 (Fig. 4B). Therefore,
we determined whether inhibition of calpains could account for
the effect of the UPS inhibitors on glutamate-induced cleavage of
GADs. Activation of calpain was measured by western blot, using
an antibody that binds specifically to the product resulting from
the cleavage of spectrin by calpains (SBDPs) [37,38,50].
Glutamate stimulation increased the formation of N-terminal
SBDPs (NSBDPs), and this effect was only slightly inhibited by
MG132 (16.6%; p,0.05) and by UBEI-41 (28.3%; p.0.05)
(Fig. 4C). These results indicate that calpain inhibition is not likely
to account for the effects of MG132 and UBEI-41 on glutamate-
evoked cleavage of GAD.
Proteasome and GAD Cleavage
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10139Figure 2. Glutamate excitotoxicity induces a time-dependent decrease in GAD65 and GAD67 protein levels in cultured
hippocampal neurons. Neurons were stimulated with 125 mM glutamate, for 20 min, and further incubated in culture conditioned medium for the
indicated period of time. Full length GAD 65/67 protein levels were determined by Western Blot with an antibody that recognizes both isoforms.
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The results shown above suggest that the proteasome plays a
direct role in GAD67 cleavage under excitotoxic conditions. In
particular, the inhibition of GAD67 cleavage by the E1 inhibitor
(Fig.4C)suggeststhattheenzymeisubiquitinatedbeforecleavageby
the proteasome. To test for the possible ubiquitination of GADs we
used the UbiQapture
TM-Q Kit which allows isolating both mono-
and poly-ubiquitinylated proteins (and their binding partners),
independent of lysine residue chain linkage. Ubiquitinated proteins
(and their binding partners) were isolated from extracts of
hippocampal neurons stimulated or not with glutamate (with or
withoutMG132),and theresultswereanalysedbyWesternBlotwith
an anti-GAD65/67 antibody. GAD65/67 was immunoprecipated
in similar amounts in all experimental conditions tested, but
stimulation with glutamate in the presence or in the absence of
MG132 increased the capture of GAD (Fig. 5A, top panel).
However, in all experimental conditions the mobility of the
immunoprecipitated GAD65/67 was the same as the mobility of
the protein present in extracts directly loaded on the gel, suggesting
that there is no change in GAD ubiquitination following glutamate
stimulation. Taken together these results suggest that GAD67
interacts with another protein(s) that is ubiquitinated, and capture of
this protein by an anti-ubiquitin antibody allows co-purification of
the enzyme. The increased co-immunopurification of GAD67 in
extracts from cells stimulated with glutamate may suggest that the
excitotoxic insult increases the ubiquitination of the GAD67
interacting protein(s).
Since the 20S proteasome is able to cleave substrates without
ubiquitination [51,52], an in vitro system was used to determine
whether this could account for the observed inhibitory effect of
MG132 on the excitotoxicity-induced cleavage of GAD65. Recom-
binant GAD65 was incubated with 20S and 26S proteasomes using
the protocol previously described [51], which allowed characterizing
the ubiquitin- and ATP-independent cleavage of YB-1 (a DNA/
RNA-binding nucleocytoplasmic shuttling protein) by the 20S
proteasome in vitro. No cleavage of recombinant GAD65 was
observed following incubation with the 20S or 26S proteasome
(Fig. 5B), suggesting that this GAD isoform does not undergo a
ubiquitin-independent proteasomal cleavage, as described for YB-1.
Control experiments using fluorogenic substrates showed that the
20S and 26S proteasome preparations were active (Fig. 5C), further
suggesting that the proteasome does not act directly on GAD65.
GADs cleavage is correlated with decreased enzyme
activity and changes the subcellular distribution
Since GADs play a key role in the synthesis of GABA from
glutamate, we investigated how the cleavage of the enzyme affects
its activity. The assay of GAD activity using the [
14C]CO2 trapping
method requires the use significant amounts of protein that cannot
be obtained using hippocampal cultures. Therefore, the effect of
GAD cleavage on the activity of the enzyme was investigated using
brain tissue from decapitated rats. Previous studies have shown that
under these conditions GAD is cleaved with a pattern similar to that
observed under excitotoxic conditions, particularly in the cerebel-
lum and in the cerebral cortex [53]. The post-mortem cleavage of
GAD65 and GAD67 in these brain regions was confirmed in the
present study (Fig. 6B), and 24 h after death there was a decrease in
the total full length GAD protein levels both in the cerebellum and
in the cerebral cortex (Fig. 6A). At this time point the activity of
GAD was decreased to 68.8% in the cerebral cortex and to 33.1%
in the cerebellum, while the total amount of full-length protein was
reduced to 73% and 58%, respectively. The total GAD protein
levels (full-length + cleaved protein) at 24 h post-mortem was not
significantly different from the amount of protein detected under
control conditions (see representative western blot in the top panel
of Fig. 6B).
GAD65 is anchored to synaptic vesicles through its N-terminus
[54,55]. Since glutamate stimulation cleaves GAD near the N-
terminal region, we hypothesized that the cleavage of the enzyme
could affect its sub-cellular localization. Under control conditions
GAD65 displays a partially punctate distribution along neurites
(Fig.7A, arrowheads), but this pattern is altered 4 h after
excitotoxic stimulation with glutamate. Under the latter conditions
some neurites show a more homogeneous distribution of GAD65,
diffuse along the neuronal processes (Fig. 7A, B), and the number
of GAD65 puncta is significantly reduced in comparison to the
control conditions (Fig. 7C). Colocalization of GAD65 with the
b2/3 GABAA receptor subunits was also significantly decreased
(Fig. 7C), showing a loss of synaptic distribution of GAD65 under
excitotoxic conditions.
Discussion
Previous studies have shown the cleavage of the glutamic acid
decarboxylase isoforms GAD65 and GAD67 under excitotoxic
Control protein levels of GAD65/67 were set to 100%. Actin was used as loading control (A). Panel A shows a representative experiment and
mean6SEM of 9 independent experiments. The cleavage of GAD67 was also analysed with an antibody directed against amino acids 70–130 of this
isoform (B). In this case the results obtained under control conditions were compared with the immunoreactivity in extracts prepared 14 h after the
toxic insult. The amino acid sequence of GAD65 (lower sequence) and 67 (top sequence) are aligned in panel C, which also show the binding sites for
the antibodies used in this study. Statistical analysis was performed using one-way ANOVA, followed by Bonferroni’s multiple comparison test.
**p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0010139.g002
Figure 3. Glutamate excitotoxicity decreases GAD65/67 mRNA.
Gene expression was analysed in cultured hippocampal neurons (7 DIV)
exposed or not to 125 mM Glutamate, for 20 min, and then returned to
the original culture medium for 4 h. For the reverse transcription
reaction 1 mg of total RNA was used. The results were normalized with
two internal control genes, GAPDH and Tubulin. Data are presented as
mean6SEM of four to five independent transcription reactions,
performed in independent preparations. Statistical analysis was
performed using Student’s t-test. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0010139.g003
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process[22–24]. In this work we show that the activity ofE1ubiquitin
ligase and the proteasome are required for glutamate-evoked
cleavage of GAD67, although no clear evidences were obtained
showing a direct ubiquitinationofthe enzyme. Furthermore, cleavage
of GAD65/67 was found to decrease enzyme activity and changed
the characteristic punctate distribution of GAD65 along neurites.
Both effects are likely to downregulate the activity of GABA as a
neurotransmitter under excitotoxic conditions.
Glutamate-induced cleavage of GAD protein levels and
downregulation of mRNA
Excitotoxic stimulation of cultured hippocampal neurons induced
the cleavage of GAD65 and 67 by a mechanism sensitive to the
calpain inhibitor ALLN, similarly to what was observed in neuronal
cultures prepared from the whole brain or from the cerebral cortex
[23,24]. The full-length proteins were cleaved into a truncated form
with approximately 55–58 kDa, which was detected by an antibody
directed against the N-terminal of GAD65 and GAD67. Since no
immunoreactive bands with low apparent molecular weight were
identified, the results indicate that both GAD isoforms are cleaved in
a sequence close to the N-terminal region of the proteins.
Accordingly, an antibody directed against amino acids 17–130 of
GAD67 also detected the cleavage product of the enzyme, showing
that the cleavage site islocated beforeamino acid130.The sequence
after amino acid 100 in GAD67 shows high homology with GAD65
(Fig. 2C), and this explains the similarity in the apparent molecular
weightofthecleavageproductsofGAD65andGAD67.Muchofthe
available evidences suggest that the N-terminal segment of GAD is
exposedandflexible[56],andthismaymakethisregionavailablefor
cleavage by proteases. In vitro studies showed that recombinant
human GAD67 lacking the first 70 or the first 90 amino acids is not
cleaved by calpain, in contrast with the full length protein [22],
suggesting that under excitotoxic conditions GAD67 may be cleaved
between amino acids 90 and 130. If this is the case, the dimerization
of GADs required for their activity is likely not affected by enzyme
cleavage since dimer formation occurs through interaction of C-
terminal portions of GAD molecules [56]. GAD is a pyridoxal 59-
phosphate (PLP)-dependent enzyme, but the co-enzyme binding site
is not contained within the N-terminal regions [57]. Therefore,
Figure 4. Proteasome and ubiquitin-activating enzyme (E1) inhibitors prevent glutamate–induced GAD65/67 cleavage. Cultured
hippocampal neurons were pre-incubated or not with 50 mM of UBEI-41 (E1 inhibitor), for 1h, or with the proteasome inhibitors MG132 (1 mM),
lactacystin (10 mM) or YU102 (10 mM), for 30 min, before excitotoxic stimulation with glutamate (125 mM), for 20 min. The cells were further incubated
in culture conditioned medium (with or without chemical inhibitors) for 5h, and the GAD65/67 immunoreactivity was assessed by western blot (A and
B). Incubation with the calpain inhibitor ALLN (10 mM) was performed under the same conditions. The average results in (A) represent the changes in
GAD65 or GAD67 immunoreactivity. In panel (B) GAD cleavage was calculated as a percentage of the total enzyme content (GAD65/67). When calpain
activity was evaluated through formation of N-terminal spectrin breakdown products (NSBDPs) the cells were incubated for 30 min after the toxic
insult (C). The effect of MG132 and UBEI-41 on calpain activation is expressed as a percentage of the activity measured in the absence of the protease
inhibitors. Results are means6SEM of 3–4 different experiments, performed in independent preparations. Statistical analysis was performed using
one-way ANOVA, followed by Bonferroni’s Multiple Comparison Test (A and B) or the Student’s t test (C). ***p,0.001.
doi:10.1371/journal.pone.0010139.g004
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GAD activity following enzyme cleavage.
In addition to the cleavage of GAD we also observed a decrease
inthemRNAlevelsforboth isoforms oftheenzymeinhippocampal
neurons subjected to an excitotoxic insult with glutamate (Fig. 3).
This is likely to limit the de novo synthesis of GAD, which could
otherwise compensate for the observed dowregulation of the full-
length protein. It remains to be determined whether the observed
decrease in the mRNA for GAD is due to a reduction in
transcription activity and/or to an active degradation of the existing
transcripts. The rapid down-regulation of GAD mRNA following
excitotoxic stimulation of cultured hippocampal neurons contrasts
with the delayed effects of ischemic injury on GAD67 mRNA [58];
unilateral ischemic lesions of the frontoparietal cortex in adult rats
increased GAD67 mRNA levels in the striatum, lasting up to 3
months after surgery. Inhibition of NMDA receptors also
downregulated GAD mRNA in various brain regions, starting at
day 2 after treatment [59], suggesting that glutamate receptors are
directly coupled to the activation of GAD67 expression.
UPS system activity is essential for excitotoxicity-induced
GAD cleavage
Previous studies have shown that calpain inhibitors fully block
[23] [or inhibit to a great extent [24]] the glutamate evoked cleavage
of GAD65/67 (see also Figure 4B), and in vitro experiments showed
thatcalpains cleaverecombinant GAD67[22].Taken togetherthese
Figure 5. GAD 65/67 are captured with an anti-ubiquitin antibody in hippocampal cultures. (A) Cultured hippocampal neurons were
stimulated or not with 125 mM glutamate for 20min, in the presence or in the absence of 10 mM MG132, and the cells were further incubated with
culture conditioned medium for 4h before preparation of the extracts. In the top panel, mono- and poly-ubiquitinylated proteins were isolated using
the UbiQapture
TM-Q Kit, and the eluted fraction [46] was subjected to western blot, using an antibody against GAD65/67. GAD65/67 total
immunoreactivity in the extracts prepared from control cells and from hippocampal neurons stimulated with glutamate is shown on the right (E.T.).
The left lane was loaded with a control provided in the kit, consisting in ubiquitinated protein lysate. The same membranes were probed for mono-
and poly-ubiquitin using an antibody included in the kit (A, middle). (B) Human recombinant GAD65 (0.75 mg) were incubated with 20/26S
proteasomes (1.5 mg) for 2h at 37uC with or without MG132. The extracts were then probed with GAD65/67 antibody. The activity of the 20S/26S
proteasomes used in the experiments was confirmed using the fluorogenic substrate suc-LLVY-MCA. The increase in fluorescence resulting from the
cleavage of the substrate was measured in relative fluorescence units (RFU) (C). The results of the capture of ubiquitinated proteins and the assay of
the recombinant GAD65 cleavage are representative of two and three independent experiments, respectively.
doi:10.1371/journal.pone.0010139.g005
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exclusive) in GAD cleavage under excitotoxic conditions. Surpris-
ingly, we observed that inhibition of the proteasome with MG132,
lactacystin or YU102 fully abrogated the cleavage of GAD67 in
hippocampal neurons subjected to excitotoxic conditions, and
MG132 had the same effect on the cleavage of GAD65.
Furthermore, inhibition of the ubiquitin-activating enzyme (E1)
with UBEI-41 also prevented the cleavage of GAD67 and GAD65.
The effects of MG132 and UBEI-41 cannot be attributed to
inhibition of calpains since the inhibitors had a small (MG132) or no
effect (UBEI-41) on the glutamate-evoked calpain activation, as
determined by measuring the formation of spectrin breakdown
products(Fig.4C).Sincethe molecularweightofthe GAD truncated
forms observed in the present studies is similar to that observed in
previous studies where calpains were shown to participate in the
cleavage of the enzyme, it is likely that the UPS and calpains act in a
co-ordinated manner to cleave GADs. If this is the case, the UPS is
likely to act upstream of calpains since no evidences were found for a
direct effect of proteasome in GAD cleavage.
Interaction between calpains and the UPS is also physiologically
relevant in other scenarios. Sequential activity of calpains and the
UPS has been proposed to contribute to the degradation of
myofibrils; calpains release myofibrils form the contractile
apparatus, which allows initiating ubiquitination and degradation
by the proteasome [60,61]. Also, degradation of IkB through
phosphorylation-dependent ubiquitination or following cleavage
by calpains is thought to release NFkB, and the transcription
factor migrates to the nucleus where it binds DNA [62–64]. There
are reports suggesting that proteasome inhibition could be
neuroprotective after stroke [31,65], namely through stabilization
of IkB and thereby preventing NF-kB activation. Inhibition of
calpains can also provide functional neuroprotection in various
animal models of cerebral ischemia [66].
The role of ubiquitination in GADs cleavage
The glutamate-evoked cleavage of GAD65/67 was sensitive to
proteasome inhibition, but incubation of GAD65 with the 20S
proteasome did not give rise to the cleavage product of the enzyme.
Although some proteins are cleaved by the 20S proteasome without
ubiquitination [51,52], this is not the case of GAD65.
Inhibition of the E1 ubiquitinating enzyme also abrogated the
cleavage of GAD65/67 under excitotoxic conditions, indicating
that protein ubiquitination plays a key role in the process.
Separation of mono and poly-ubiquitinated proteins with the
UbiQapture
TM-Q Kit allowedrecoveringGAD65and GAD67,but
although there was an increase in the amount of GAD isolated with
the kit under excitotoxic conditions the apparent molecular weight
of the proteins isolated was similar to that observed in whole cell
extracts. This strongly suggests that GAD is not ubiquitinated, but
instead interacts with a protein which state of ubiquitination is
increased following excitotoxic stimulation with glutamate. This
may be related with an increase in ubiquitin mRNA transcripts, as
observed following ischemia [67,68], with an impairment of the
proteasome activity [29,30,69], and/or to a signalling cascade
induced by excitotoxicity that may ultimately leads to the
ubiquitination of the GAD binding partner. Excitotoxicity also
regulates the NF-kB transcription factor after cerebral ischemia
through ubiquitination and degradation of its binding partner IkB
[70]. Similarly, the cleavage of GAD may follow the increase in
ubiquitination and degradation of a binding partner, which may
allow cleavage of the enzyme by calpains. This hypothesis explains
the effect of both E1 inhibition and proteasome inhibition on GAD
cleavage, and the results showing no apparent ubiquitination of the
enzyme (present work), and the role of calpains [24]. The GAD
binding partner that may be involved in the regulation of the
protein under excitotoxic conditions remains to be identified.
Interestingly, the proteasome inhibitors showed differential
effects on GAD65 and GAD67 cleavage induced by excitotoxic
stimulation with glutamate. MG132 abrogated the cleavage of both
GAD isoforms, in contrast with YU102 and lactacystin which were
only effective against the cleavage of GAD67. The difference in the
effects of the inhibitors tested may be due to their specificities:
MG132 and YU102 act preferentially on the cheymotrypsin-like
and caspase-like activities of the proteasome, respectively, whereas
lactacystin targets preferentially the trypsin-like and caspase-like
activities [43,48]. Assuming that under excitotoxic conditions the
proteasome targets a GAD binding partner before cleavage of the
Figure 6. Excitotoxicity-induced decrease in GAD65/67 activity.
Heads of adult Wistar rats were decapitated and processed immediately
or kept for 24 h at room temperature. The extracts were used for both
GAD activity measurements and Western Blot analysis. GAD activity was
determined using a trapping technique for radiolabelled [
14C]CO2
brought by GAD65/67 activity, and was expressed as nmol CO2/hr/mg
of protein (A). Full-length GAD65/67 protein levels from the same
extracts were determined by Western Blot using an anti-GAD65/67
antibody, and control protein levels of GAD65/67 were set to 100% (B).
Data are presented as mean6SEM of 3 to 4 independent experiments.
Statistical analysis was performed using Student’s t-test. *p,0.05;
**p,0.01: ***p,0.001.
doi:10.1371/journal.pone.0010139.g006
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substrates bound to each of the GAD isoforms are distinct.
Alterations of GADs activity and localization under
excitotoxic conditions
The decrease in GADs activity observed in post mortem cerebral
cortices to 74% was correlated with a decrease to 73% of the full-
length protein found in the extracts analysed by WesternBlot; in the
cerebellum the GAD activity decrease to 48% in post mortem extracts
relative to control, and a down-regulation of the full-length protein
to 58% was observed. This decrease in enzyme activity following N-
terminal cleavage is in agreement with previous results obtained
using a similar experimental paradigm [53] and with the effect of
calpain cleavage at the N-terminal region on the activity of
recombinant GAD67 [22]. Incontrast,truncationofthe N-terminal
region of recombinant GAD65 increased enzyme activity [71] and
trypsin cleavage of recombinant GAD65 and GAD67 at their N-
terminal region was shown to increase enzyme activity [56]. The
difference between the effects observed in brain extracts and in in
vitro experiments may be due to interaction of GAD with regulatory
proteins (see below), which are absent when recombinant proteins
are used. Post-translational modifications of GAD, such as
phosphorylation, may also contribute to the differences in the effect
of N-terminal cleavage on the activity of the enzyme measured in
brain extracts or using recombinant protein [72]. A decrease in
enzyme activity in neurons subjected to excitotoxic conditions may
activate compensatory mechanisms in surviving neurons since the
expression of GAD is regulated by the abundance of GABA by a
mechanism independent of the activation of GABA receptors
[73,74]. However, within the time frame analysed after the
excitotoxic insult we found no evidences for an upregulation of
GAD protein levels from de novo protein synthesis (Fig. 2).
In this work we also found that excitotoxic stimulation of
cultured hippocampal neurons changes the subcellular distribution
of GAD65, with a loss of protein clustering along neurites. This is
in agreement with the results showing a role for palmitoylation of
Cys30 and Cys45 in GAD65 in the post-Golgi trafficking of the
protein to presynaptic clusters [75,76]. The N-terminal truncation
under excitotoxic conditions is likely to separate this targeting
sequence from the catalytic domain of GAD65, dissociating the
enzyme from synaptic vesicles as suggested in the results of the
immunocytochemistry experiments shown in Fig. 7. Furthermore,
the decrease in colocalization of GAD65 and the b2/3 GABAA
receptor subunits suggests that the cleaved protein becomes more
diffuse, moving away from the synapse.
It was proposed that association of GAD with membranes and
the anchoring of the enzyme to synaptic vesicles occur first
through formation of a complex with the heat shock protein 70
family member HSC70 (heat shock cognate 70), followed by
interaction with cysteine string protein (CSP), an integral protein
of the synaptic vesicle [54]. Cleavage or degradation of the GAD
anchoring proteins may release the enzymes anchored to synaptic
vesicles and may contribute to change the subcellular distribution
of the enzyme under excytotoxic conditions. If the N-terminal
region of GAD65 plays a role in the interaction with the anchoring
proteins, the cleavage of the enzyme under excitotoxic conditions
may also explain the observed changes in immunoreactivity after
the toxic insult with glutamate. The interaction of GAD with
HSC70 and synaptic vesicles also promotes the activity of the
enzyme [54]. The release of GAD65 from synaptic vesicles that
may occur under excitotoxic conditions would explain, at least in
part, the decrease in enzyme activity observed in cerebellar and
cerebrocortical extracts containing cleaved GAD.
The anchoring ofGAD65 to synaptic vesiclesthrough interaction
with the vesicular GABA transporter may allow coupling the
synthesis of GABA to the packaging of the neurotransmitter into the
vesicles [17]. The cleavage of the N-terminal region of GAD65 and
the consequent dissociation of the enzyme from synaptic vesicles
and from the synapse may decrease the accumulation of GABA in
the vesicles and, therefore, may deregulate GABAergic synapses.
This is particularly relevant considering that GAD65 is the isoform
responsible for the synaptically released GABA [77].
In conclusion, we showed that excitotoxic conditions lead to the
cleavage of GAD65/67 in cultured hippocampal neurons in a
UPS-dependent manner. GAD cleavage decreased enzyme
activity and changed the subcellular distribution of the 65KDa
isoform, which should decrease GABA production and may affect
the accumulation of the neurotransmitter in synaptic vesicles.
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